# US 2025/0154558 A1 · Methods and systems for analyzing nucleic acid molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154558 A1
- Document ID: US20250154558A1
- Status: Published application
- Kind: A1
- Application number: 19/025,566
- Filed: 2025-01-16
- Published: 2025-05-15
- Earliest claimed: 2016-12-22
- Assignees: Guardant Health, Inc.
- Applicants: Guardant Health, Inc.
- Inventors: Andrew KENNEDY
- Web page: https://patentgrep.com/patent/US20250154558A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides methods for processing nucleic acid populations containing different forms (e.g., RNA and DNA, single-stranded or double-stranded) and/or extents of modification (e.g., cytosine methylation, association with proteins). These methods accommodate multiple forms and/or modifications of nucleic acid in a sample, such that sequence information can be obtained for multiple forms. The methods also preserve the identity of multiple forms or modified states through processing and analysis, such that analysis of sequence can be combined with epigenetic analysis.

## Claims

### Claim 1

A method comprising:
a) providing one or more populations of cell-free DNA from a biological sample from a subject;
b) fractionating the one or more populations of cell-free DNA based on characteristics that are present at different levels in cell-free DNA derived from cancerous compared to noncancerous cells, thereby generating subpopulations of cell-free DNA, wherein the characteristics are:
(i) methylation level of the cell-free DNA; and
(ii) protein modifications of histones;
c) amplifying at least one of the subpopulations of cell-free DNA; and
d) sequencing at least one of the amplified subpopulations of cell-free DNA.

### Claim 2 (depends on 1)

The method of claim 1, wherein step c) comprises amplifying the subpopulation of cell-free DNA enriched for methylation of cell-free DNA and the subpopulation of cell-free DNA enriched for protein modifications of histones.

### Claim 3 (depends on 2)

The method of claim 2, wherein step d) comprises sequencing the amplified subpopulation of cell-free DNA enriched for methylation of cell-free DNA and the amplified subpopulation of cell-free DNA enriched for protein modifications of histones.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biological sample is plasma.

### Claim 5 (depends on 4)

The method of claim 4, wherein the biological sample is about 1 ml of plasma.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject has cancer or has been diagnosed as being susceptible to having cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cancer is lung cancer.

### Claim 8 (depends on 1)

The method of claim 1, wherein the fractionating comprises immunoprecipitation.

### Claim 9 (depends on 8)

The method of claim 8, wherein the fractionating based on the methylation level of cell-free DNA is performed using an antibody specific for 5-methylcytosine.

### Claim 10 (depends on 8)

The method of claim 8, wherein the fractionating based on the protein modifications of histones is performed using an antibody specific to modified histones.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method further comprises mapping sequence reads obtained from the sequencing to one or more loci on a reference sequence; and analyzing the sequence reads to detect the methylation level and/or protein modification of histones at the one or more loci.

### Claim 12 (depends on 11)

The method of claim 11, wherein the analyzing comprises analyzing the methylation level and/or protein modification of histones at the one or more loci relative to a normal sample at the one or more loci.

### Claim 13 (depends on 11)

The method of claim 11, wherein the method further comprises using a trained classifier to classify the subject based on the methylation level and/or protein modification of histones at the one or more loci.

### Claim 14 (depends on 13)

The method of claim 13, wherein the trained classifier classifies the methylation level and/or protein modification of histones at the one or more loci as associated with a tissue in the subject.

### Claim 15 (depends on 13)

The method of claim 13, wherein the trained classifier classifies the methylation level and/or protein modification of histones at the one or more loci as associated with a type of cancer in the subject.

### Claim 16 (depends on 11)

The method of claim 11, wherein the methylation level and/or protein modification of histones at the one or more loci are indicative of gene expression or status of a disease.

### Claim 17 (depends on 11)

The method of claim 11, wherein profiles of the methylation level and/or protein modification over time are used in the selection of a therapy for the subject.

### Claim 18 (depends on 11)

The method of claim 11, wherein the method comprises monitoring residual disease or recurrence of disease.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cell-free DNA comprises circulating tumor DNA.

### Claim 20 (depends on 1)

The method of claim 1, wherein the methylation level is 5-methylcytosine level.
